Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients: The GENERATIONS Trial, A Pharmacodynamic and Pharmacokinetic Study in Stable Coronary Artery Disease Patients - ERLINGE, David; GURBEL, Paul A; CHUNMEI ZHOU; MOSER, Brian A; JAKUBOWSKI, Joseph A; SMALL, David S; WINTERS, Kenneth J; ANGIOLILLO, Dominick J; JAMES, Stefan; LINDAHL, Tomas L; SVENSSON, Peter; TEN BERG, Jurrien M; et al. (Journal of the American College of Cardiology, 2013)
Keywords: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Biological and medical sciences; Cardiology. Vascular system; Coronary Angiography; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - drug therapy; Coronary Artery Disease - mortality; Coronary heart disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart; Humans; Male; Medical sciences; Middle Aged; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - pharmacokinetics; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacokinetics; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes - administration & dosage; Thiophenes - adverse effects; Thiophenes - pharmacokinetics; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Treatment Outcome; Human; Patient; Cardiovascular disease; Coronary heart disease; Biological activity; Antiplatelet agent; Prasugrel; Generation; Platelet; Young adult; Antithrombotic agent; Clinical trial; Circulatory system; Inhibition; Cardiology; Pharmacokinetics; Elderly; Age; coronary artery disease; RPA; prasugrel; light transmission aggregometry; nonelderly (≥45 to <65 years of age); maintenance dose; elderly; residual platelet aggregation; high on-treatment platelet reactivity; platelet reactivity; HPR; very elderly (≥75 years of age); AUC(0-t(last)); vasodilator-associated stimulated phosphoprotein platelet reactivity index; maximum platelet aggregation; area under the concentration-time curve, time 0 to last quantifiable concentration ≤4 h post-dose; MD; pharmacokinetic; CAD; VE; PD; NE; LTA; pharmacodynamic; PK; VASP-PRI; MPA